Clinical trials
Lymphoma, Mantle-Cell trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Active, not recruiting | 10 |
| Recruiting | 7 |
| Terminated | 3 |
| Unknown status | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 5 |
| Acerta Pharma BV | 3 |
| BeOne Medicines | 3 |
| Celgene | 2 |
| Eli Lilly and Company | 2 |
| European Mantle Cell Lymphoma Network | 2 |
| Loxo Oncology, Inc. | 2 |
| Pharmacyclics LLC. | 2 |
| Polish Lymphoma Research Group | 2 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Mantle-Cell | 39 |
| Lymphoma, Non-Hodgkin | 13 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 |
| Lymphoma, B-Cell, Marginal Zone | 11 |
| Lymphoma, Follicular | 11 |
| Lymphoma, Large B-Cell, Diffuse | 9 |
| Waldenstrom Macroglobulinemia | 9 |
| Lymphoma | 8 |
| Lymphoma, B-Cell | 7 |
| Recurrence | 3 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.